159 related articles for article (PubMed ID: 36117043)
1. Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide.
Tremblay D; Baine I; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1067-e1074. PubMed ID: 36117043
[TBL] [Abstract][Full Text] [Related]
2. Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia.
Mascarenhas J
Expert Rev Hematol; 2022 Aug; 15(8):671-684. PubMed ID: 35983661
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Verstovsek S; Mesa R; Talpaz M; Kiladjian JJ; Harrison CN; Oh ST; Vannucchi AM; Rampal R; Scott BL; Buckley SA; Craig AR; Roman-Torres K; Mascarenhas JO
Haematologica; 2022 Jul; 107(7):1599-1607. PubMed ID: 34551507
[TBL] [Abstract][Full Text] [Related]
4. New approaches to tackle cytopenic myelofibrosis.
Reynolds SB; Pettit K
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
[TBL] [Abstract][Full Text] [Related]
5. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
Sastow D; Mascarenhas J; Tremblay D
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248
[TBL] [Abstract][Full Text] [Related]
6. Managing patients with myelofibrosis and low platelet counts.
Al-Ali HK; Vannucchi AM
Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
[TBL] [Abstract][Full Text] [Related]
7. Alleviating anemia and thrombocytopenia in myelofibrosis patients.
Cervantes F; Correa JG; Hernandez-Boluda JC
Expert Rev Hematol; 2016 May; 9(5):489-96. PubMed ID: 26891375
[TBL] [Abstract][Full Text] [Related]
8. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
9. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
Tremblay D; Mascarenhas J
Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
[TBL] [Abstract][Full Text] [Related]
11. Managing patients with myelofibrosis and thrombocytopenia.
Yilmaz M; Verstovsek S
Expert Rev Hematol; 2022 Mar; 15(3):233-241. PubMed ID: 35316110
[TBL] [Abstract][Full Text] [Related]
12. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
13. Novel strategies for challenging scenarios encountered in managing myelofibrosis.
Bose P; Mesa RA
Leuk Lymphoma; 2022 Apr; 63(4):774-788. PubMed ID: 34775887
[TBL] [Abstract][Full Text] [Related]
14. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
Diaz AE; Mesa RA
Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
[TBL] [Abstract][Full Text] [Related]
15. How I manage anemia related to myelofibrosis and its treatment regimens.
Verstovsek S
Ann Hematol; 2023 Apr; 102(4):689-698. PubMed ID: 36786879
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
17. Anemia in myelofibrosis: Current and emerging treatment options.
Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
[TBL] [Abstract][Full Text] [Related]
18. Pacritinib for myelofibrosis in adults with thrombocytopenia.
Yang DH; Lu Q; Zhu Z; Huang G; Young K
Drugs Today (Barc); 2022 Dec; 58(12):577-589. PubMed ID: 36651066
[TBL] [Abstract][Full Text] [Related]
19. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis.
Mascarenhas J; Migliaccio AR; Kosiorek H; Bhave R; Palmer J; Kuykendall A; Mesa R; Rampal RK; Gerds AT; Yacoub A; Pettit K; Talpaz M; Komrokji R; Kremyanskaya M; Gonzalez A; Fabris F; Johnson K; Dougherty M; McGovern E; Arango Ossa J; Domenico D; Farnoud N; Weinberg RS; Kong A; Najfeld V; Vannucchi AM; Arciprete F; Zingariello M; Falchi M; Salama ME; Mead-Harvey C; Dueck A; Varricchio L; Hoffman R
Clin Cancer Res; 2023 Sep; 29(18):3622-3632. PubMed ID: 37439808
[TBL] [Abstract][Full Text] [Related]
20. Biological drivers of clinical phenotype in myelofibrosis.
Mascarenhas J; Gleitz HFE; Chifotides HT; Harrison CN; Verstovsek S; Vannucchi AM; Rampal RK; Kiladjian JJ; Vainchenker W; Hoffman R; Schneider RK; List AF
Leukemia; 2023 Feb; 37(2):255-264. PubMed ID: 36434065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
